论文部分内容阅读
目的探讨心肌桥患者发生动脉硬化的机制及阿托伐他汀对其影响。方法185例患者根据冠脉造影结果,分为心肌桥组、冠脉狭窄组和对照组,并对心肌桥患者服用阿托伐他汀,检测各组患者及心肌桥患者服用阿托伐他汀前后的细胞粘附因子。结果心肌桥组与冠脉狭窄组相比,sICAM-1、sVCAM-1、sE-selectin差异无统计学意义(P>0.01),与对照组相比,sICAM-1、sVCAM-1、sE-selectin差异有统计学意义(P<0.01)。心肌桥组患者服药前后相比,sI-CAM-1、sVCAM-1、sE-selectin差异有统计学意义(P<0.01)。结论心肌桥患者可有动脉粥样硬化的发生,应积极对心肌桥患者进行干预,服用阿托伐他汀有抗动脉硬化作用。
Objective To investigate the mechanism of atherosclerosis in patients with myocardial bridge and the effect of atorvastatin on it. Methods 185 patients were divided into myocardial bridge group, coronary artery stenosis group and control group according to the results of coronary angiography. And atorvastatin was administered to patients with myocardial bridge to detect the changes of atorvastatin Cell Adhesion Factor. Results There was no significant difference in sICAM-1, sVCAM-1 and sE-selectin between myocardial bridge group and coronary artery stenosis group (P> 0.01). Compared with control group, sICAM-1, sVCAM- selectin difference was statistically significant (P <0.01). The levels of sI-CAM-1, sVCAM-1 and sE-selectin in patients with myocardial bridge before and after treatment were significantly different (P <0.01). Conclusion Myocardial bridge patients may have atherosclerosis, myocardial infarction patients should be actively intervened, taking atorvastatin anti-atherosclerosis.